Insitro vs Manus AI

Side-by-side comparison of AI visibility scores, market position, and capabilities

Manus AI leads in AI visibility (63 vs 27)

Insitro

EmergingBiotechnology

ML Drug Discovery

Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.

AI VisibilityBeta

Overall Score

D27

Category Rank

#1 of 1

AI Consensus

72%

Trend

Per Platform

ChatGPT

Perplexity

Gemini

About

Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.

Full profile

Manus AI

ChallengerAI & Machine Learning

Autonomous AI Agents

General-purpose autonomous AI agent. $125M+ revenue run rate. Acquired by Meta for $2B+ (Dec 2025). Founded 2022, China/Singapore. MIT Innovators Under 35.